Halimi Jean-Michel
Service de néphrologie-immunologie clinique, Hôpital Bretonneau, Université François Rabelais, CHU Tours, F-37044 Tours, France.
Presse Med. 2009 Apr;38(4):621-6. doi: 10.1016/j.lpm.2009.01.008. Epub 2009 Feb 13.
Renal artery stenosis may be due to atheromatous disease or renal fibromuscular dysplasia (FMD). Management of both diseases requires treatment of hypertension usually observed in such patients; however, clinical presentation, mechanism and treatment of these 2 diseases are usually different. Renal FMD is now considered as a systemic disease, the cause of which may be genetic (although the exact cause is still elusive). Renal arteries are the most frequent localizations of FMD, but extra renal arteries may also be involved (usually carotid arteries). Risk factors of hypertension-induced renal FMD include estrogen treatment and smoking. Renal FMD are mostly found in young women and in children who present with recent severe and/or refractory symptomatic hypertension. Diagnosis is usually easy (Doppler, CT-scan), and treatment of renal FMD is angioplasty in most cases. Atheromatous renal artery stenosis is usually found in patients with other atheromatous disease (peripheral artery disease, carotid, coronary artery disease...). Clinical presentation include severe or refractory hypertension, recurrent flash pulmonary edema in a patient with hypertension, progressive renal dysfunction spontaneously or after medical treatment with converting-enzyme inhibition or angiotensin II blockade, hypertension in a patient (usually smoker or ex-smoker) with diffuse atheromatous vascular disease. Management of atheromatous renal artery disease is medical treatment in all patients (aggressive treatment of cardiovascular risk factors, control of arterial pressure); revascularization is required in some patients only since it rarely cures hypertension: the goal of revascularization is mostly renal function protection, which may be observed in selected patients. Revascularization must be decided by physicians or teams involved in the care of such patients. Patients with atheromatous renal artery disease are at very high renal and cardiovascular risk : aggressive management of cardiovascular risk factors is crucial.
肾动脉狭窄可能由动脉粥样硬化疾病或肾纤维肌发育不良(FMD)引起。这两种疾病的治疗都需要处理这类患者中常见的高血压;然而,这两种疾病的临床表现、机制和治疗通常有所不同。肾FMD现在被认为是一种全身性疾病,其病因可能是遗传性的(尽管确切病因仍不清楚)。肾动脉是FMD最常见的发病部位,但肾外动脉也可能受累(通常是颈动脉)。高血压所致肾FMD的危险因素包括雌激素治疗和吸烟。肾FMD多见于年轻女性和近期出现严重和/或难治性症状性高血压的儿童。诊断通常很容易(多普勒超声、CT扫描),大多数情况下肾FMD的治疗是血管成形术。动脉粥样硬化性肾动脉狭窄通常见于患有其他动脉粥样硬化疾病(外周动脉疾病、颈动脉、冠状动脉疾病……)的患者。临床表现包括严重或难治性高血压、高血压患者反复出现的急性肺水肿、自发或在使用转换酶抑制剂或血管紧张素II阻滞剂进行药物治疗后出现的进行性肾功能不全、患有弥漫性动脉粥样硬化血管疾病的患者(通常是吸烟者或既往吸烟者)出现的高血压。动脉粥样硬化性肾动脉疾病的治疗对所有患者均采用药物治疗(积极控制心血管危险因素、控制动脉血压);仅部分患者需要血管重建,因为血管重建很少能治愈高血压:血管重建的主要目标是保护肾功能,部分患者可能会出现这种情况。血管重建必须由负责此类患者护理的医生或团队决定。患有动脉粥样硬化性肾动脉疾病的患者存在非常高的肾脏和心血管风险:积极控制心血管危险因素至关重要。